Advice on drug safety in pregnancy: Are there differences between commonly used sources of information?

Drug Safety

Volumn 31, Issue 9, 2008, Pages 799-806

  Frost Widnes, Sofia K ^a   Schjøtt, Jan ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Drug information; Pharmacovigilance; Pregnancy

Indexed keywords

ANTIDEPRESSANT AGENT; ERYTHROMYCIN; GENERIC DRUG; LORATADINE; MIRTAZAPINE;

ARTICLE; CARDIOVASCULAR MALFORMATION; CLINICAL DECISION MAKING; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG INFORMATION; DRUG INFORMATION CENTER; DRUG SAFETY; DRUG UTILIZATION; FIRST TRIMESTER PREGNANCY; HUMAN; INFORMATION SYSTEM; NORWAY; PATIENT EDUCATION; PREGNANCY; PRIORITY JOURNAL; PUBLICATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SECOND TRIMESTER PREGNANCY; STATISTICAL ANALYSIS; TERATOGENICITY; THIRD TRIMESTER PREGNANCY;

DRUG INDUSTRY; DRUG INFORMATION SERVICES; DRUG LABELING; FEMALE; HUMANS; NORWAY; PHARMACEUTICAL PREPARATIONS; PILOT PROJECTS; PREGNANCY; PREGNANCY TRIMESTERS; RISK ASSESSMENT;

EID: 49749097945     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831090-00008     Document Type: Article

References (26)

1. Mitchell AA. Systematic identification of drugs that cause birth defects: a new opportunity. N Engl J Med 2003 Dec 25; 349 (26): 2556-9
2. Irl C, Hasford J. Assessing the safety of drugs in pregnancy: the role of prospective cohort studies. Drug Saf 2000 Mar; 22 (3): 169-77
3. Webster WS, Freeman JA. Prescription drugs and pregnancy. Expert Opin Pharmacother 2003 Jun; 4 (6): 949-61
4. Hancock RL, Koren G, Einarson A, et al. The effectiveness of Teratology Information Services (TIS). Reprod Toxicol 2007 Feb; 23 (2): 125-32
5. Koren G. Maternal-fetal toxicology: a clinician's guide. 3rd ed. New York: Dekker, 2001
6. Della-Giustina K, Chow G. Medications in pregnancy and lactation. Emerg Med Clin North Am 2003 Aug; 21 (3): 585-613
7. Bjerrum L, Foged A. Patient information leaflets: helpful guidance or a source of confusion? Pharmacoepidemiol Drug Saf 2003 Jan-Feb; 12 (1): 55-9
8. Ronning M, Blix HS, Harbo BT, et al. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose: are drug utilisation data comparable? Eur J Clin Pharmacol 2000 Dec; 56 (9-10): 723-7
9. Goodwin J, Rieder S, Rieder MJ, et al. Counseling regarding pregnancy: related drug exposures by family physicians in Ontario. Can J Clin Pharmacol 2007 Winter; 14 (1): e58-69
10. Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf 2000 Sep; 23 (3): 245-53
11. Sannerstedt R, Lundborg P, Danielsson BR, et al. Drugs during pregnancy: an issue of risk classification and information to prescribers. Drug Saf 1996 Feb; 14 (2): 69-77
12. Myhr K. Can we rely on drug information [in Norwegian]? Tidsskr Nor Laegeforen 2002 Nov 10; 122 (27): 2644-6
13. Fusier I, Tollier C, Husson MC. Infovigilance: reporting errors in official drug information sources. Pharm World Sci 2005 Jun; 27 (3): 166-9
14. Petersen MN, Christensen HR, Kristensen MB. Lack of consensus on drug interactions: a descriptive analysis of information on interactions in the Laegemiddelkatalog, Medicinfortegnelse and product descriptions [in Danish]. Ugeskr Laeger 2005 Aug 29; 167 (35): 3286-90
15. Bergk V, Haefeli WE, Gasse C, et al. Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. Eur J Clin Pharmacol 2005 Jul; 61 (5-6): 327-35
16. Kimland E, Bergman U, Lindemalm S, et al. Drug related problems and off-label drug treatment in children as seen at a drug information centre. Eur J Pediatr 2007 Jun; 166 (6): 527-32
17. Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr 2005 Sep; 164 (9): 552-8
18. The Norwegian Pharmaceutical Products Compendium (Felleskatalogen). 2007 edition. Oslo, Norway: Norwegian Medicine Agency, 2007
19. European Commission. EudraLex: the rules governing medicinal products in the European Union. Volume 2A: procedures for marketing authorization. Chapter 2: mutual recognition. Brussels: European Commission, 2005
20. Lagoy CT, Joshi N, Cragan JD, et al. Medication use during pregnancy and lactation: an urgent call for public health action. J Womens Health (Larchmt) 2005 Mar; 14 (2): 104-9
21. Kasilo O, Romero M, Bonati M, et al. Information on drug use in pregnancy from the Viewpoint Regional Drug Information Centre. Eur J Clin Pharmacol 1988; 35 (5): 447-53
22. Guilhem D, Castex V, Soubrie C. Possible exploitation of a pharmacovigilance center concerning the risk of teratogenesis [in French]. Therapie 1993 Jan-Feb; 48 (1): 47-9
23. Schjott J, Pomp E, Gedde-Dahl A. Quality and impact of problem-oriented drug information: a method to change clinical practice among physicians? Eur J Clin Pharmacol 2002 Feb; 57 (12): 897-902
24. Schjott J, Pomp E, Gedde-Dahl A, et al. What do health professionals ask RELIS Vest service and how satisfied are they with the answers [in Norwegian]? Tidsskr Nor Laegeforen 2000 Jan 20; 120 (2): 204-7
25. Addis A, Impicciatore P, Miglio D, et al. Drug use in pregnancy and lactation: the work of a regional drug information center. Ann Pharmacother 1995 Jun; 29 (6): 632-3
26. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977 Mar; 33 (1): 159-74